KDM4C inhibition reinforces NK cell cytotoxicity through the cGAS-STING pathway in TP53-mutated AML
Blocking a specific protein makes aggressive leukemia cells self-destruct and become invisible to immune cells, while simultaneously awakening those immune cells to attack more aggressively.
KDM4C inhibition with QC6352 induces senescence in TP53-mutated AML cells (rather than apoptosis), activates cGAS-STING signaling, upregulates NK-activating ligands, and enhances NK cell cytotoxicity; in vivo combination of QC6352 with NK cell therapy reduced leukemic burden and prolonged murine survival. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- in_vitro_and_in_vivo_preclinical
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Aging and Disease
Why it surfaced
Mechanistically novel discovery: KDM4C inhibitor converts TP53-mutant AML cells from apoptosis-resistant to senescence-prone, and cGAS-STING activation creates an NK-cell killing vulnerability. This addresses one of the most treatment-refractory AML subtypes with a credible combination immunotherapy approach. Preclinical only, but conceptually strong with clear translational path.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.